더바이오 11월 5일 주요뉴스
https://www.thebionews.net/edit/webzine.html?idxno=677
● 제약바이오 3Q 실적 희비…고수익 제품·신사업 성과로 셀트리온·대웅 ‘약진’
https://www.thebionews.net/news/articleView.html?idxno=29863
● [분석] BMS, 오름과 ‘ORM-6151’ 계약 종료 왜?…후속 ‘ORM-1153’의 차별성은
https://www.thebionews.net/news/articleView.html?idxno=29897
● [컨콜] 노보 ‘위고비필’ 3Q 매출 1조원 돌파…‘카그리세마’ 내년 美 출시 추진
https://www.thebionews.net/news/articleView.html?idxno=29867
● 베링거, 中 시노와 ADC·T세포 TCE 항암 후보 9.7조원 규모 라이선스 딜
https://www.thebionews.net/news/articleView.html?idxno=29865
● “넥스트 반도체는 바이오”…국가 자문기구 3곳, ‘바이오 대혁신’에 한 목소리
https://www.thebionews.net/news/articleView.html?idxno=29910
● 뉴릭스 “사노피, ‘STAT6 분해제’ 1상 중단”…최대 6100억원 후속 기술료 무산
https://www.thebionews.net/news/articleView.html?idxno=29896
● 지아이, GI-102·J&J 차세대 T세포 인게이저 병용 글로벌 임상 첫 환자 투약
https://www.thebionews.net/news/articleView.html?idxno=29885
● ‘K바이오’, 제2의 반도체 신화 도전…투자 확대·규제 혁신 모색
https://www.thebionews.net/news/articleView.html?idxno=29888
● 오스코텍, 밸류업 이행 현황 공개…기술이전·흑자전환 목표 조기 달성
https://www.thebionews.net/news/articleView.html?idxno=29911
● 동아에스티, 디앤티홀딩컴퍼니 지분 약 399억원 규모 전량 매각
https://www.thebionews.net/news/articleView.html?idxno=29912
● ‘“10초 투여’로 심장 진단 편의성↑”…GE헬스케어, ‘라피스캔’ 국내 상륙
https://www.thebionews.net/news/articleView.html?idxno=29898
● SK바이오팜, 3분기 영업익 1000억원 넘겼다…누적 3000억원 돌파(종합)
https://www.thebionews.net/news/articleView.html?idxno=29895
● SK바이오사이언스, 3Q 매출 전년比 21%↑…세전이익 흑자전환
https://www.thebionews.net/news/articleView.html?idxno=29918
● 큐로셀, ASH서 '림카토' 장기 추적 결과 공개…장기반응군 3년 생존율 81.6%
https://www.thebionews.net/news/articleView.html?idxno=29879
● 디앤디파마텍 ‘바이오 유럽 2026’ 참가…글로벌 파트너링 논의
https://www.thebionews.net/news/articleView.html?idxno=29905
● 지투지바이오, 美 PODD 이어 ‘바이오유럽’ 참가…글로벌 기술사업화 속도
https://www.thebionews.net/news/articleView.html?idxno=29883
● 신라젠, ‘BAL0891’ 美 1상 변경 신청…요로상피암 병용요법 평가
https://www.thebionews.net/news/articleView.html?idxno=29916
● HLB이노 美 자회사 베리스모, CAR-T 임상1상서 반응률 80%·완전관해 60%
https://www.thebionews.net/news/articleView.html?idxno=29880
● 바이오엔테크, 3Q 매출 감소에도 흑자 전환…이중항체·ADC 개발 확대
https://www.thebionews.net/news/articleView.html?idxno=29848
● ABL Bio pursues global collaboration for BBB shuttle and 4-1BB bispecific antibodies at BIO Europe
https://www.thebionews.net/news/articleView.html?idxno=29919
● Y-Biologics expands global business development built on ‘Multi-AbKine’ at BIO Europe
https://www.thebionews.net/news/articleView.html?idxno=29915
● HLB Innovation's U.S. subsidiary Verismo reports 80% response rate and 60% complete remission in Phase 1 CAR-T clinical trial
https://www.thebionews.net/news/articleView.html?idxno=29909
● Curocell reveals 3-year long-term follow-up results of 'RIMQARTO' at ASH, with long-term responder group posting 81.6% 3-year survival rate
https://www.thebionews.net/news/articleView.html?idxno=29908
● G2GBIO joins ‘BIO Europe’ after U.S. PODD, speeding up global technology commercialization
https://www.thebionews.net/news/articleView.html?idxno=29907
● D&D Pharmatech heads into Phase 1 trials for liver fibrosis drug candidate in 2027 – “Oral peptide development expanding”
https://www.thebionews.net/news/articleView.html?idxno=29906
● Samsung Bioepis signs U.S. marketing rights deal with Teva for two biosimilar autoimmune disease treatments
https://www.thebionews.net/news/articleView.html?idxno=29891
● GI Innovation Initiates Global Clinical Trial of GI-102 in Combination with Next-Generation T cell engager, Dosing First Patient
https://www.thebionews.net/news/articleView.html?idxno=29890
● Celltrion reveals preclinical results for world's first 'quadruple-action obesity treatment' candidate
https://www.thebionews.net/news/articleView.html?idxno=29884
● HLB, Elevar's liver cancer drug candidate enters FDA 'full review,' with April 2027 set as target review date
https://www.thebionews.net/news/articleView.html?idxno=29864
*제약바이오 11월 5일 아침 유튜브 라디오 뉴스(매일 아침 업로드)
https://www.youtube.com/watch?v=Jv8wfMwQJAM